ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Rosenberg’s Gene Transfer Protocol Approved By NIH Advisory Group

October 7, 1988

Cancer Advocacy: Deal Returns $3M to Office of Women’s Health, Spends $3.5M On Workshops

August 1, 1997

Letrozole Cuts Risk Of Breast Cancer Recurrence Even After Tamoxifen Use

March 28, 2008

Abbott PCR Test For HCV Load Sensitive to Within 12 IU/mL

May 27, 2011

Groups Lobby Congress For $5.8 Billion Budget For NCI, Increases For Other Programs

June 18, 2010

HEW Finally Moves On Distribution Of Chemicals

September 7, 1979